Astrazeneca (AZN) Raw Materials (2015 - 2025)

Astrazeneca (AZN) has reported Raw Materials for 11 consecutive years, with $1.9 billion the latest figure, recorded in Q4 2025.

• In Q4 2025, Raw Materials rose 24.71% year-over-year to $1.9 billion; the TTM figure through Dec 2025 stood at $1.9 billion (up 24.71% YoY), while the FY2025 annual figure was $1.9 billion, up 24.71% from the prior year.
• Raw Materials came in at $1.9 billion for Q4 2025 at Astrazeneca, up from $1.5 billion in the prior quarter.
• The five-year high for Raw Materials was $1.9 billion in Q4 2025, with the low at $1.4 billion in Q4 2022.
• Average Raw Materials over 5 years is $1.6 billion, with a median of $1.5 billion recorded in 2023.
• Across the five-year window, Raw Materials soared 39.06% in 2021 and slipped 18.97% in 2022, its largest moves.
• Year by year, Raw Materials stood at $1.8 billion in 2021, then retreated by 18.97% to $1.4 billion in 2022, then climbed by 7.67% to $1.5 billion in 2023, then retreated by 2.74% to $1.5 billion in 2024, then increased by 24.71% to $1.9 billion in 2025.
• According to Business Quant data, Raw Materials over the past three periods registered $1.9 billion, $1.5 billion, and $1.5 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.